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ABSTRACT 
Objective: This research work aimed to assess the capability of endophytic Streptomyces sp. IPBCC. b.15.1539 isolated from Tinospora crispa in 
producing α-glucosidase inhibitor compound and examined the effect of its ethyl acetate extract containing α-glucosidase inhibitor in lowering 
blood glucose in streptozotozin mice.  
Methods: Streptomyces sp. IPBCC. b.15.1539 was grown in a bioreactor filled with International Streptomyces Project 2 medium, for 5, 10, 15, and 
20 days, and assayed for its in vitro α-glucosidase inhibitory activity. The ethyl acetate extract was examined for its IC50
Results: The crude extract produced 
 value. An in vivo experiment 
was set up using thirty mice, which were divided into five treatment groups: (a) acarbose (0.03 mg/30 g body weight) used as a positive control, (b) 
placebo used as a negative control, (c-e) treatment groups were treated with ethyl acetate extract at 0.036 mg/30 g body weight (P1), 0.36 mg/30 g 
body weight (P2), 0.036 mg/30 g body weight (P3).  
98.5% α-glucosidase inhibitory activity, with 15,6 biomass after 10 days of production. The ethyl acetate 
extract at a concentration of 1000 µg/ml produced 96.08% α-glucosidase inhibitory activity, while acarbose at the same concentration gave 97.46% 
inhibition. The IC50 for the ethyl acetate extract
Conclusions: The 
 was 0.047 µg/ml, while for acarbose was 0.003 µg/ml. The ethyl acetate extract applied as the P1 
treatment group lowered blood glucose levels in streptozotozin mice by 26%.  
α-glucosidase inhibitor of Streptomyces sp. IPBCC. b.15.1539 of T. crispa has the potency as an antidiabetic agent for type 2 DM 
therapy.




Global diabetes mellitus (DM) prevalence data shows serious 
increases. The total number of diabetics worldwide is projected to 
rise from 171 million in 2000 to 366 million in 2030 [1] and become 
the growing global problem of overweight, obesity and physical 
inactivity. Both modern and traditional antidiabetic therapies have 
been used to treat people with type 2 DM, which is the most 
common form of DM. Type 2 DM comprises 90% of people with 
diabetes around the world [2]. One of the modern antidiabetic drug 
treatment mechanisms is based on α−glucosidase inhibitor activity, 
which inhibits the absorption of glucose from the intestine to the 
blood. Acarbose is a pseudo-oligosaccharides which acts as a 
competitor for α-glucosidase, non digestible and non-toxic. 
Tinospora crispa has been studied for its potential antidiabetic 
treatment mechanism. Water extract of T. crispa significantly 
lowered blood glucose levels and increased plasma insulin levels in 
diabetic rats [13]. This effect may be due to 
The α-
glucosidase inhibitor of acarbose is used in the therapy of type 2 DM 
(non-insulin-dependent) [3, 4]. On the other hand, various medicinal 
plants have been traditionally used to treat diabetics. Recent 
scientific evidence supports the use of the medicinal plants in DM 
therapy, e. g. Terminalia arjuna; Tinospora crispa, T. cordifolia, 
Lagerstroemia speciosa; Andrographis paniculata, Phaleria 
macrocarpa, Curcuma aeruginosa, C. xanthoriza, Centela asiatica, 
Xoncus arvensis, Caesalpinia sappan, Alloe vera, Parcia speciosa, 
Gynura procumbens, Physalis peruviana, Hibiscus sabdariffa, Tribulus 
terrestris, and Berberis aristata [5-12].  
the modulation of 
Ca2+concentration in pancreatic beta cells [14]. Other data showed 
that T. crispa treatment reduced plasma glucose levels as much as 
7.45% for 40 days in rats induced by streptozotozin
Actinomycetes are known to produce bioactive compounds with 
various biological function including α-glucosidase inhibition. 
Published data on actinomycetes which function as an α-glucosidase 
inhibitor, have been mainly on non-endophytic actinomycetes. 
Supporting evidence is available for Actinoplanes sp. 
 [15]. These 
evidences clearly show that T. crispa has potency as a source of 
antidiabetic compounds. However, T. crispa, a herbaceous climbing 
plant, is considered to be slow growing. A huge amount of biomass 
and consistent supply is required to produce active compounds at a 
large scale. Therefore, although there is no doubt that T. crispa has 
an antidiabetic potency, its slow growth is a major constraint to its 
widespread application. For that reason, new approaches should be 
shought, e. g. exploring the capability of endophytic microbes 
especially actinomycetes which reside in T. crispa plant tissue and 
can function as antidiabetic compound producers.  
SE50/110 [16, 
17], Actinoplanes sp. CKD485-16 [18], Streptomyces glaucescens [19], 
Micromonospora sp. VITSDK3 (EU55138) [20], and Actinoplanes sp. 
A56
Our previous work demonstrated that α-glucosidase inhibitor, an 
antidiabetic compound, associated with T. crispa was also produced 
by its endophytic actinomycetes. Several endophytic actinomycetes 
are found to reside in T. crispa, and they are capable of producing 
the α-glucosidase inhibitor similar to that of their host plant. 
Production of the α-glucosidase inhibitor by T crispa seems to be 
influenced by the contribution of its endophytic actinomycetes [23]. 
Amongst the isolated endophytic actinomycetes of T. crispa, 
 [21]. Nowdays, acarbose which was originally isolated from 
Actinoplanes sp. from Africa has been successfully commercialized as 
an antidiabetic drug [22].  
Streptomyces sp. IPBCC. b.15.1539 has been selected, due to its high 
potency as a source of α-glucosidase inhibitor. Here, we describe our 
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further work on the effect of ethyl acetate extract containing α-
glucosidase inhibitor produced by Streptomyces sp. IPBCC. b.15.1539 
in lowering blood glucose of streptozotozin diabetic mice. The 
described findings are the first report in elucidating the role of 
endophytic actinomycetes from T. crispa which can lower blood 
glucose in streptozotozine mice. Data from the in vivo experiments 
clearly support the in vitro assessment for the capability of 
Streptomyces sp. IPBCC. b.15.1539 as antidibetic agent through its 
MATERIALS AND METHODS 
α-
glucosidase inhibitory activity. The microbial based approach may 
be more efficient for producing antidiabetic compounds than the 
host plant especially for very slow growing T. crispa plant. 
Growth and production of metabolites 
Streptomyces sp. IPBCC. b.15.1539 (1% volume) was grown in a 
bioreactor filled with ISP 2 medium, for 5, 10, 15, and 20 days, and 
assayed for its α-glucosidase inhibition. The optimum time for the 
production of α-glucosidase inhibitor was determined based on the 
in vitro α-glucosidase inhibitory activity produced by crude extract 
and ethyl acetate extract containing the active compounds
α-glucosidase inhibitory activity  
. 
The stock enzyme solution was prepared by adding 1 mg of α-
glucosidase (Sigma) into 100 ml phosphate buffer pH 7 containing 200 
mg Bovin Serum Albumin. A total of 1 ml of the stock enzyme solution 
was 25 times diluted with phosphate buffer pH 7. The substrate 
solution consisted of 50 µl of 20 mM p-nitrophenyl α-D-
glucopyranoside, 50 µL of phosphate buffer pH 7 and 10 µl of dimethyl 
sulfoxide solution (DMSO). The mixture was incubated for 5 min at 37 
°C, then 50 µl of phosphate buffer solution and the enzyme was added, 
and incubated for further 15 min. The reaction was stopped by adding 
800 µl of 200 mM sodium carbonate. The released P-nitrophenol 
absorbance was measured using a spectrophotometer (Thermo 
Spectronic Genesys 20) at 400 nm wavelength. Acarbose (Glucobay; 
Bayer), the commercial α-glucosidase inhibitor, was used as a 
comparison. A concentration of 50 mg acarbose was diluted until 1% 
(w/v) concentration. Inhibition activity of crude extracts containing α-
glucosidase inhibitor was calculated as percentage of inhibition by the 
following formula: [(C-S)/C x 100%, where C is the control absorbance 
and S is the sample absorbance [24]. 
IC50 of ethyl acetate extract containing 
The IC
α-glucosidase inhibitor 
50 value was obtained by testing the inhibitory activity of the 
extract at different concentrations, i.e. 1000 µg/ml, 500 ug/ml, 250 
µg/ml, 125 ug/ml, and 62.5 µg/ml [25]. The line graph equation was 
made as a function of the extract concentration (x) and an inhibition 
activity produced (y). 
Acclimatization  
Mice were acclimatized in cages for 7 days in order to adjust to the 
new environment. The in vivo experiment was conducted by 
considering the animal ethics conduct. Cages were placed in the 
room with the dark and light arrangement each for 12 hours, at 
room temperature with humidity around 49-64%. Feed containing 
25% protein, 3% fat, 5% crude fiber, 10% ash, and 12% moisture 
content and distilled water, were given ad libitum
Anti-hyperglycemic activity based on oral glucose tolerant test 
(OGTT)  
.  
Mice were divided into 6 groups which each group consisted of 5 
mice. The mice were fasted for 6 hours and still be given a drink, 
then the blood was taken for determination of initial glucose levels. 
Group 1 was given a 10% sucrose solution (90 mg/30 g bw), group 2 
as a negative control was given distilled water, and group 3 as a 
positive control was given acarbose (0.03 mg/30 g bw), groups of 4 
to 6 were given treatment group of ethyl acetate extract each at 
0.036 mg/30 g bw (P1), 0.36 mg/30 g bw (P2), 3.6 mg/30 g bw (P3). 
After 30 minutes, all groups were orally given 10% sucrose solution 
(90 mg/30 g bw). Then the blood sample was taken at 30, 60, 120 
and 180 minutes after administration. Blood glucose levels were 
calculated by glucometer (GlucoDr) and then the percentage of 
blood glucose levels was calculated 26]. 
Anti-hyperglicemic assay using streptozotozin induction in 
mice 
Mice were fasted for 6 hours and intravenously injected with 
streptozotozin which previously dissolved in 50 mM sodium citrate 
pH 4.5 at a dose of 40 mg/kg. After 15 days of treatment, the mice 
which experienced an increase in glucose levels above 150 mg/dl 
were classified as diabetic mice
The diabetic 
 [27].  
mice were divided into 5 groups, each group consisting 
of 6 mice which were given treatment for 15 days. Group 1 was 
given distilled water as a negative control, group 2 as a positive 
control was given acarbose (0.03 mg/30 g bw), group 3, 4, and 5 
were given treatment of ethyl acetate extract each at 0.036 mg/30 g 
bw (P1), 0.36 mg/30 g bw (P2), 3.6 mg/30 g bw (P3). At 5, 10, and 
15 days after treatment, the mice tails were cut at the tip, then the 
blood glucose levels were measured using glucometer (GlucoDr), 
and calculated the percentage of changing blood glucose levels 
Data analysis  
[26]. 
The experiment was set up using a completely randomized design 
(CRD). All data were shown as mean values±standard deviation 
(mean±SD). Data were analyzed using the Statistical Analysis System 
(SAS) program version 9.1.3 based on analysis of variance (ANOVA) 
and followed by Duncan test 5% significance level
RESULTS 
. 
α-glucosidase inhibitory activity  
The data showed that α-glucosidase inhibitory activity of the crude 
extracts and the average weight of biomass increased at 5-10 days of 
the production time and decreased in 15-20 days (fig.1). The crude 
extract containing α-glucosidase inhibitor showed 98.5% of α-
glucosidase inhibitory activity after 10-days of production, with 15.6 




Fig. 1: The α-glucosidase inhibitory activity and biomass 
production of Streptomyces sp. IPBCC. b.15.1539 grown at ISP2-
medium for 5-20 days at room temperature.  
 
The inhibitory activity of ethyl acetate extract containing α-
glucosidase inhibitor at a concentration of 1000 µg/ml was 96.08%, 
while acarbose at the same concentration gave 97.46% inhibition 
(table 1). The higher concentration of α-glucosidase inhibitor 
increased the percentage value of α-glucosidase inhibition
 
. 
Table 1: Activity of ethyl acetate extract containing α-
Concentration (µg/ml) 
glucosidase inhibitor produced by Streptomyces sp. IPBCC. 
b.15.1539 
Inhibition (%) 
Acarbose Ethyl acetate extract  
62.5 88.13 83.33 
125 88.89 86.60 
250 91.53 90.85 
500 96.33 93.46 
1000 97.46 96.08 
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Results of logarithmic equation showed that y = 4.6686 In 
(x)+64.287 with R2 = 0.9908 (fig. 2a). The value of x = 0.047 ug/ml. 
The results were then compared with acarbose which showed y = 
3.7654In (x)+71.677 with R2 =0.9417 and x = 0.003 ug/ml. The IC50 
of acarbose was lower than the IC50 value of α-glucosidase inhibitor 




Fig. 2: The IC50 value of α-glucosidase inhibitor produced by 
Streptomyces sp. IPBCC. b.15.1539 (a) and acarbose (b) Anti-
hyperglicemic activity of OGTT 
 
The anti-hyperglicemic effect of ethyl acetate extracts containing α-
glucosidase inhibitor produced by Streptomyces sp. IPBCC. b.15.1539 
is shown in fig. 3. In in vivo data showed that giving of 10% sucrose 
(90 mg/30 g bw) sharply increased blood glucose levels of mice and 
reached the highest value after 60 min. Blood glucose levels 
decreased toward normal in 2 to 3 hours of observation. Treatment 
with ethyl acetate extracts containing α-glucosidase inhibitor 
produced by Streptomyces sp. IPBCC. b.15.1539 could inhibited the 




Fig. 3: Normal and hyperglicemic blood glucose level and 
acarbose for mice treated with ethyl acetate extract of 
Streptomyces sp. IPBCC. b.15.1539 (1, 10 dan 100 times 
sequentially).  P1 extract,  P2 extract,  P3 
extract,  sucrose,  positive control, and 
negative control 
 
Data analysis of variance at 95% level of confidence indicated that 
the administration of P3 treatment (3.6 mg/30 g bw) of ethyl acetate 
extract was significantly different from 10% sucrose treatment (90 
mg/30 g BW) (table 2). Further, the P3 treatment was significantly 
different to P1 and P2. The area under the curve (AUC) between 
blood glucose levels over time showed 626.5 mg. hour/dL AUC 
values after administration of the 10% sucrose (table 2). Giving 
acarbose to the treated mice caused 34 % decreased in AUC values 
which became 413.3 mg. hour/dL. Meanwhile, the ethyl acetate 
extract containing a-glucosidase inhibitor produced by Streptomyces 
sp. IPBCC. b.15.1539 at a concentration of P1, P2 and P3 were able to 
reduce the AUC value by 10%, 18.9
 
% and 24.7%, respectively. 
Table 2: The effect of ethyl acetate extracts containing a-glucosidase inhibitor produced by Streptomyces sp. IPBCC. b.15.1539 in lowering 
blood glucose level of mice after 180 minutes treatment 
AUC of blood glucose level (mg. hour/dl) (N=5) 
Mice Sucrosa Control- Control+ P1 P2 P3 
 X±SE 626.5±137.4 413.3±46.1 422.75±61.5 546.15±81.9 508.±103.1 471.7±72.1 
AUC 100 %*) 65.96%a 67.47%c 90.04%c 81.09%ba 75.29%ba 
Reduced AUC 
bc 
34.04% 32.53% 9.96% 18.91% 24.71% 
(*) Number followed by similar letter at similar row does not indicate the differences amongst treatments based on Duncan test at 5% level of significant. 
 
Anti-hyperglicemic activity in streptozotozin mice 
Testing the antihyperglicemic activities with the low-dose of 
streptozotozin induction (Multiple low-dose Streptozotozin 
(MLDSTZ)) showed that the ethyl acetate extract capable of lowering 
blood glucose level from day 5 to day 15 (
 
fig. 4).  
 
Fig. 4: Changing of blood glucose level in diabetic mice induced 
by streptozotozin for 15 days treatment.  P1,  P2, 
 P3,  Positive Control,  Negative Control 
 
Fig. 5: Changing of blood glucose level in diabetic mice induced 
by streptozotozin after 15 days treatment.  Day 0,  Day 15, 
 % of reduced blood glucose. K-: negative control; K+: 
positive control; P1, P2, P3: treatment 
Kolmogorov-Smirnov test indicated that the data was normally 
spreaded. The analysis of variance at the 95% level of confidence 
showed that there was a significant effect amongst the treatments. 
The P1 difference from to P2, P3, negative control and positive 
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control. These indicated that the ethyl acetate extract of 
Streptomyces sp. IPBCC. b.15.1539 capable of lowering blood glucose 
levels of diabetic streptozotozin mice. The highest decreased in 
blood glucose levels was by 26% and it was found at day 15 for mice 




The highest α-glucosidase inhibitory activity is correlated with the 
average of biomass produced by Streptomyces sp. IPBCC. b.15.1539 
grown on ISP-2 medium for 10 days. Production of secondary 
metabolites and biomass are influenced by the growth conditions 
such as nutritional composition. The ISP-2 medium contains malt 
extract and yeast extract as a source of nutrients and glucose as a 
carbon source. The high of α-glucosidase inhibitory activity probably 
due to relatively rapid cell growth for 10 days in a bioreactor, which 
then slowing down the activity and growth on the day 15 to 20. The 
old cells is associated with the process of sporulation. At the final 
phase of their life cycle, microbial cells need to adapt to unfavorable 
environmental conditions, which may cause the production of 
secondary metabolites [28]. Microbes need water, energy sources, 
carbon, nitrogen, minerals, and vitamins for nutrients and oxygen 
for aerobic processes [29]. The production of secondary metabolites 
requires media that can stimulate cell growth. The production of -
glucosidase inhibitor by Streptomyces sp. IPBCC. b.15.1539 may be 
stimulated by nutrient limitations that exist in a bioreactor used 
during the production period
Microbial natural products are considered as important sources of 
various lead compounds used in pharmaceutical industry. 
Actinomycetes is known as source of various important 
commercially microbial natural products used in the medical field. 
Acarbose as an α-glucosidase inhibitor is produced by member of 
Actinomycetes, e. g. strains of the genera Actinoplanes and 
Streptomyces. Acarbose is produced industrially using developed 
strains of Actinoplanes sp. SE50/100 [30], and it is known as 
.  
the 
most potential inhibitor of the sucrose metabolism through 
inhibition of the activity of α-glucosidase [31] used in the treatment 
of type 2 diabetes disease. Acarbose works as a competitive inhibitor 
of α-glucosidase enzyme that catalyzes the break glycosidic bond in 
the release of glucose, which causes inhibition of glucose absorption, 
resulting in lower glucose levels after eating.  
The α-glucosidase is an enzyme that can hydrolyze the substrate likes 
p-nitrophenyl-α-D-glucopyranose into product, e. g. p-nitrophenol and 
glucose [24]. Diabetics treated with α-glucosidase inhibitor like 
acarbose will enabling them to better utilize starch-or sucrose-
containing diets by slowing down the intestinal release of α-D-glucose. 
Acarbose able to inhibit the activity of sucrase, maltase, dextrinase, 
and glucoamylase [30]. The acarbose, as α-glucosidase inhibitor works 
as the competitor for the enzyme, thus blocking the active site of the 
enzyme. The α-glucosidase inhibitor binds to the substrate in the form 
of enzyme substrate complex and produces the p-nitrophenol and 
glucose. The enzyme activity was measured by the absorbance of p-
nitrophenol which gave the yellow colour. The difference in 
absorbance value of the sample with or without addition of the 
enzyme represents the percentage of α-glucosidase inhibitory activity. 
In this work, we found that endophytic Streptomyces sp. IPBCC. 
b.15.1539 isolated from an antidiabetic medicinal plant namely T. 
crispa proved to have capability as the source of α-glucosidase 
inhibitor. The IC50 value is the concentration of the extract value 
which gave 50% of the α-glucosidase inhibitory activity. The IC50 for 
the ethyl acetate extract was 0.047 µg/ml, while for acarbose was 
0.003 µg/ml. The data indicate that IC50 value of ethyl acetate 
extract containing α-glucosidase inhibitor was much higher than 
acarbose. This condition may be related to the degree of purity of 
the extract. Acarbose is a commercial product in the form of pure 
preparations potent inhibitor of the activity of sucrose metabolism 
[31]. The lower the IC50 value, the higher the activity of the active 
compounds in inhibiting the activity of α-glucosidase. The intensity 
of inhibition in the sample are categorized as very active if it is able 
to produce α-glucosidase inhibition at concentrations of less than 50 
µg/ml [32], which is also showed by the sample used in this 
research work.  
For the antihyperglycemic activity of oral glucose tolerance test 
(OGTT), it clearly shows that the ethyl acetate extract containing α-
glucosidase inhibitor produced by Streptomyces sp. IPBCC. b.15.1539 
has the potency in lowering postprandial blood glucose levels of 
mice after the administration of 10% sucrose solution. The ethyl 
acetate extract containing α-glucosidase inhibitor is capable to 
lowering blood glucose levels in hyperglycemic diabetic mice. This 
phenomenon indicates that the ethyl acetate extract containing α-
glucosidase inhibitor has promissing to be further developed as 
antidiabetic agent. In addition, the α-glucosidase inhibitor produced 
by Streptomyces sp. IPBCC. b.15.1539 may have other different 
active metabolites produced. Acarbose belongs to the class of 
pseudooligosacharide [30], while the ethyl acetate extract 
containing α-glucosidase inhibitor produced by Streptomyces sp. 
IPBCC. b.15.1539 has been assayed for the present of flavonoid [25]. 
It has been reported that the flavonoid component has the ability to 
suppress postprandial hyperglycemic blood glucose levels [33]. 
Flavonoids given orally to diabetic mice, capable to lower plasma blood 
glucose levels by increasing glucose uptake in peripheral tissues and 
regulate the activity of the expression of enzymes involved in 
carbohydrate metabolism pathway [34]. Active compounds from plants 
Cynanchum acutum L. i.e. quersetin, tamarixtin and kempferol had 
antidiabetic activity by lowering blood glucose levels [35]. Flavonoids 
such as quersetin can stimulate cell division pancreatic beta cells that 
produce insulin secretion [36]. The data reinforces the notion that the 
ethyl acetate extract containing α-glucosidase inhibitor produced by 
Streptomyces sp. IPBCC. b.15.1539 has potential as α-glucosidase 
inhibitor as well as antihyperglycemic in diabetic mice
ACKNOWLEDGEMENT 
. 
We thank to Directorate General of Higher Education, Ministry of 
Research, Tehnology and Higher Education, Republic of Indonesia 
for the research grant and to Bogor Agricultural University for the 
support facilities. 
CONFLICT OF INTERESTS 
Declared None 
REFERENCES 
1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of 
diabetes: estimates for the year 2000 and projections for 2030. 
Diabetes Care 2004;27:1047-53. 
2. [WHO] World Health Organization. 10 Facts about Diabetes. 
Geneva; 2014. 
3. Laube H. Acarbose. An update of its therapeutic use in diab etes 
treatment. Clin Drug Invest 2002;22:141-56. 
4. Wehmeier UF, Piepersberg W. Biotechnology and molecular 
biology of the α-glucosidase inhibitor acarbose. Appl Microbiol 
Biotechnol 2004;63:613-25. 
5. Bnouham M, Ziyyat A, Mekhfi H, Tahri A. Medicinal plants with 
potential antidiabetic activity–a review of ten years of herbal 
medicine research. Int J Diabetes Metab 2006;14:1-25.  
6. Klein G, Jaekyung Kim, Klaus Himmeldirk, Yanyan Cao, 
Xiaozhuo Chen. Antidiabetes and anti-obesity activity of 
Lagerstroemia speciosa. eCAM 2007;4:401-7. 
7. Lamba HS, Bhargava CS, Thakur M, Bhargava S. Alpha 
glucosidase and aldolase reductase inhibitory activity in vitro 
and anti diabetic activity in vivo of Tribulus terrestris L. (Dunal). 
Int J Pharm Pharm Sci 2011;3(3):270-2.  
8. Morshed MA, Haque A, Rokeya B, Ali L. Anti-hyperglycemic and 
lipid lowering effect of Terminalia arjuna bark extract on 
streptozotozin induced type 2 diabetic model rats. Int J Pharm 
Pharm Sci 2011;3(4):449-53. 
9. Patela MB, Mishrab SM. Magnoflorine from Tinospora cordifolia 
stem inhibits α-glucosidase and is antiglycemic in rats. 
J Funct Foods 2012;4:78-86. 
10. Puranik N, Kammar KF, Devi S. Anti-diabetic activity of 
Tinospora cordifolia (Willd) in Streptozotozin diabetic rats; 
does it act like surfonylureas? Turk J Med Sci 2010;40:265-70. 
Lestari et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 6, 235-239 
239 
11. Subramanian R, Asmawi MZ, Sadikun A. Effect of ethanolic 
extract of Andrographis paniculata nees on a combination of 
fat-fed diet and low dose streptozotozin induced chronic 
insulin resistance in rats. Diabetol Croat 2008;37:13-22.  
12. Upwar N, Patel R, Waseem N, Mahobia NK. Hypoglycemic effect 
of methanolic extract of Berberis aristata DC stem on normal 
and streptozotozin induced diabetic rats. Int J Pharm Pharm Sci 
2011;3(1):222-4. 
13. Noor H, Aschroft SJH. Pharmacological characterisation of the 
antihyperglycemic properties of Tinospora crispa extract. J 
Ethnopharm 1998;62:7-13. 
14. Sriyapai C, Rawadee DU, Somkiat S, Ngampong, Sarinee K. 
Hypoglycemic effect of Tinospora crispa dry powder in 
outpatients with metabolic syndrome at king chulalongkorn 
memorial hospital. J Health Res 2009;23:125-33. 
15. Grover JK, Vats V, Rathi SS, Dawar R. Tradition Indian 
antidiabetic plants attenuate progressive renal damage in 
streptozotozin induced diabetic mice. J Ethnopharmocol 
2003;81:233-40. 
16. Stratmann A, Mahmud T, Lee S, Distler J, Floss HG, Piepersberg 
W. The AcbC Protein from Actinoplanes Species Is a C7
17. Zhang. Identification of a 1-epi-valienol 7-kinase activity in the 
producer of acarbose, Actinoplanes sp. FEBS Lett 2003;540:53-7. 
-cyclitol 
synthase related to 3-dehydroquinate synthases and is 
involved in the biosynthesis of the α-glucosidase inhibitor 
acarbose. J Biol Chem 199;274:10889-96. 
18. Choi BT, Shin CS. Reduced formation of byproduct component c 
in acarbose fermentation by Actinoplanes sp. CKD485-16. 
Biotechnol 2003;19(6):1677-82. 
19. Rockser Y, Wehmeier UF. The gac-gene cluster for the 
production of acarbose from Streptomyces glaucescens GLA. O: 
Identification, isolation and characterization. J Biotechnol 
2008;140:114-23. 
20. Suthindhiran K. Alpha glucosidase and alpha amylase 
inhibitory activity of Micromonospora sp. VITSDK3 
(EU551238). IJIB 2009;6(3):115-20. 
21. Wei S. Medium optimization for acarbose production by 
Actinoplanes sp. A56 using the response surface methodology. 
Afr J Biotechnol 2010;9(13):1949-54. 
22. McGown J. Diabetes drug produced by a microbe in out of 
africa: mysteries of access and benefit sharing. Beth Burrows 
(Ed). Washington (US): The Edmonds Institute; 2006. 
23. Pujiyanto S, Yulin L, Antonius S, Sri B, Latifah KD. Alpha-
glucosidase inhibitor activity and characterization of 
endophytic actinomycetes isolated from some Indonesian 
diabetic medical plants. Int J Pharm Pharm Sci 2012;4:328-33. 
24. Moon HE, Islam MN, Ahn Br, Chowdry SS, Shin HS, Jung HA, et 
al. Protein tyrosine 1 B and α-glucosidases inhibitory 
phylotonins from edible brown algae, Eicklonia stolonifera and 
Eisena bicyclis. Biosci Biotechnol Biochem 2011;75:1472-80.  
25. Pujiyanto S. The activity of α-glucosidase inhibitor and 
characterization of endophytic actinomycetes isolated from 
several antidiabetes medicinal plants. [Disertation]. Bogor 
Agricultural University; 2012. 
26. Kambouche N, Merah B, Derdour A, Bellahouel S, Bouayed J, 
Dicko A, Younos C. Hypoglycemic and antihyperglycemic effects 
of Anabasis articulata (Forssk) Moq (Chenopodiaceae), an 
Algerian medicinal plant. Afr J Biotechnol 2009;8:5589-94. 
27. Wu KK, Youming H. Streptozotozin-induced diabetic models in 
mice and rats. Pharmacol 2008;47:1-14. 
28. Maier RM, Pepper IL, Gerba CP. Environmental Microbiology. 
Canada (CA): Academic Pr; 2000. 
29. Waites. Industrial Microbiology: An Introduction. London (UK): 
Blackwell Science; 2001. 
30. Mahmud T. The C7
31. Ghadyale V, Shrihari T, Vivek H, Akalpita A. Effective control of 
postprandial glucose level through inhibition of intestinal alpha 
glucosidase by Cymbopogon martinii (Roxb.). eCAM 2012;10:1-6. 
N aminocyclitol family of natural products. 
Nat Prod Rep 2003;20:137-66. 
32. Jun. Comparisont of antioxidant activities of isoflavones from 
kudzu root (Pueraria labata ohwl). J Food Sci 2003;68:2117-22. 
33. Tadera K, Yuji M, Kouta T, Tomoko M. Inhibition of α-
glucosidase and α-amylase by flavonoids. J Nutr Sci Vitaminol 
2006;52:149-53. 
34. Bramachari G. Bio-flavonoids with promising antidiabetic 
potentials: A critical survey. Res Signpost India 2011;1:187-212. 
35. Fawzy C, Hossam MA, Mohammed SAM, Fathy MS, Amani AS. 
Antidiabetic and antioxidant activities of major flavonoids of 
Cynanchum acutum L. (Asclepiadaceae) Growing in Egypt. Z 
Naturforsch 2008;63:658-62. 
36. Mahesh T, Menon PV. Quercetin alleviates oxidative stress in 
streptozotozin induced diabetic rats. Phytother Res 
2004;18:123-7.
 
